$22 million was raised by Vitestro, an autonomous blood drawing business situated in Utrecht, Netherlands.
The company’s solution reduces the need for manual handling and improves patient and clinician satisfaction by enabling hospitals and laboratories to perform accurate and autonomous blood draws with a mix of artificial intelligence (AI), sophisticated imaging technology, and robots.
By the end of this year, a number of Vitestro devices that have already been pre-ordered will be installed at various hospitals around Europe. Additionally, the business is now in charge of the A.D.O.P.T. trial, a sizable assessment of its self-contained blood collection tools. and plans to get its device approved by the CE by the end of 2024.
Investors
- The European Innovation Council Fund (EIC Fund)
- Invest-NL
- Sonder Capital
- NYBC Ventures (led the round) including participation from current private investors as well.
This increased the organization’s total amount of funding to $50 million (€46 million) from grant and equity investments.
The money will be used by the business to grow the workforce in order to fulfill customer demand for its robotic blood draw equipment and create new features for the product.
About Vitestro
Founded in 2017, Vitestro is dedicated to enhancing the blood draw experience for patients and clinicians through the use of autonomous technology and a team of over 70 experts in medical robotics, artificial intelligence, imaging software, and healthcare commercialization. The company is led by CEO Toon Overbeeke and commercial director Brian Joseph.
